argenx SE American Depositary Shares
ARGX · Nasdaq
Next quarter
Reports Oct 29, 2026.
Consensus is $7.62 EPS for Sep 2026 across 7 estimates, ranging $6.39 to $8.77.
ARGX Jun 2026
- 19.41%
- -0.69%
- $6.13
- $7.32
- —
- —
Highlights
- Earnings beat: Reported EPS was $7.32 versus consensus of $6.13, a 19.41% upside surprise.
- VYVGART sales: First-half product net sales rose 62% year over year to $2.813 billion from $1.739 billion, with the United States contributing $2.380 billion.
- Profit growth: First-half profit increased to $838 million from $415 million, while basic EPS rose to $13.47 from $6.80.
- Operating leverage: First-half operating profit reached $887 million versus $340 million a year earlier, despite R&D and SG&A expenses increasing to $929 million and $772 million, respectively.
- Expanded label: U.S. VYVGART and VYVGART Hytrulo labels now cover all adult gMG serotypes, including anti-AChR, anti-MuSK, anti-LRP4 and triple-seronegative patients.
- Pipeline catalysts: Topline results are expected in the third quarter of 2026 for the registrational ALKIVIA myositis study and in the fourth quarter for the EMPASSION multifocal motor neuropathy study.
- Cash generation: Operating cash flow was $651 million in the first half, up from $362 million a year earlier; cash and equivalents ended June at $3.584 billion.
- FcRn expansion: The VYVGART SC autoinjector is positioned for launch in 2027, while ARGX-213 is Phase 3 ready and ARGX-124 is expected to complete Phase 1 by year-end 2026.
Analysis
argenx delivered a strong June 2026 quarter, with EPS of $7.32 beating the $6.13 consensus estimate by 19.41%. The supplied release does not provide the comparable prior-quarter income statement, so the quarter-on-quarter change cannot be measured directly. On the available half-year figures, the business was materially ahead of the year-ago period: VYVGART product sales rose 62% to $2.813 billion, total operating income increased to $2.854 billion from $1.775 billion, and profit doubled to $838 million from $415 million.
The defining feature of the print was continued commercial execution around VYVGART alongside sharply higher investment in the platform. R&D spending rose 45% to $929 million and SG&A increased 28% to $772 million, yet operating profit expanded to $887 million from $340 million. argenx also broadened the U.S. gMG label to all serotypes, increasing the addressable market, while maintaining a dense catalyst calendar: ALKIVIA results are expected in Q3 2026, EMPASSION results in Q4, and an autoinjector launch is targeted for 2027. Operating cash flow reached $651 million and total cash and current financial assets were $5.184 billion at June 30.
VYVGART commercial momentum
VYVGART remained the central driver of the quarter and first-half performance. Product net sales reached $2.813 billion in the six months ended June 30, up from $1.739 billion in the prior-year period. U.S. sales accounted for $2.380 billion, or roughly 85% of the total, while Japan contributed $169 million and the rest of the world $247 million. China declined to $17 million from $33 million.
- Label expansion: U.S. VYVGART and VYVGART Hytrulo now cover all adult gMG serotypes, including anti-AChR-Ab, anti-MuSK-Ab, anti-LRP4-Ab and triple-seronegative disease.
- Future access: The company remains on track for a VYVGART SC autoinjector launch in 2027 across all approved indications.
- Commercial concentration: Three U.S. customers represented approximately 72% of first-half product net sales, compared with five customers representing 85% in the year-ago period.
Earnings and investment
The sales increase translated into significant operating leverage even as argenx funded a broader development and commercial organization. First-half operating profit rose to $887 million from $340 million, and profit increased to $838 million from $415 million. Financial income was $92 million, while exchange losses of $19 million compared with exchange gains of $76 million a year earlier.
- R&D investment: R&D expense increased to $929 million from $642 million, primarily reflecting registrational work on efgartigimod, empasiprubart and adimanebart, alongside early-stage programs.
- Commercial infrastructure: SG&A rose to $772 million from $601 million, including $240 million of marketing services and $145 million of professional fees.
- Tax impact: Income tax expense increased to $119 million from $74 million, comprising $230 million of current tax expense and a $110 million deferred tax benefit.
Pipeline catalyst calendar
argenx is moving from a single-product growth story toward a broader immunology portfolio, with multiple registrational readouts and new indications expected over the next two years.
- Near-term readouts: Topline ALKIVIA results in myositis are expected in Q3 2026, followed by EMPASSION results in multifocal motor neuropathy in Q4 2026.
- Additional VYVGART opportunities: The company expects to expand into ocular myasthenia gravis following positive ADAPT OCULUS results. ADVANCE-NEXT in primary ITP is expected in the first half of 2027, and UNITY in Sjogren’s disease in the second half of 2027.
- Empasiprubart: Registrational CIDP studies EMVIGORATE and EMNERGIZE are expected to produce topline data in the second half of 2027, while ADAPT-Forward is evaluating empasiprubart as an add-on to efgartigimod in gMG.
- Pipeline breadth: argenx expects ten molecules in clinical development by the end of 2026; ARGX-213 is Phase 3 ready and ARGX-124 is expected to complete Phase 1 by year-end.
Cash and balance sheet
argenx continued to build liquidity from the VYVGART franchise while deploying cash into financial assets and development. Operating cash flow was $651 million in the first half versus $362 million a year earlier. Cash and equivalents increased to $3.584 billion from $3.491 billion at December 31, while current financial assets rose to $1.600 billion from $949 million.
- Liquidity: Cash, cash equivalents and current financial assets totaled $5.184 billion at June 30, 2026.
- Working capital: Trade and other receivables increased to $1.931 billion from $1.647 billion, while inventories declined to $371 million from $474 million.
- Manufacturing commitments: Outstanding commitments under commercial supply agreements with Lonza and Fujifilm totaled approximately $1.2 billion.
